Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.
Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Jason J. Luke(UPMC Hillman Cancer Center), Toshio Shimizu(Kansai Medical University), C. Talluto(Novartis (United States)), Neeltje Steeghs(Peter MacCallum Cancer Centre), Nitya Nair(490 BioTech (United States)), Shahneen Sandhu(Peter MacCallum Cancer Centre), Andrew Bean(Tris Pharma (United States)), Nancy Lewis(Tris Pharma (United States)), Anna Spreafico(Princess Margaret Cancer Centre), Reinhard Dummer(University of Zurich), Robert J. Brown(Aduro BioTech (United States)), Sinead Dolan(Novartis (United States)), Stefan Kasper(Essen University Hospital), Damian Trujillo(Aduro BioTech (United States)), Omid Hamid(Memorial Sloan Kettering Cancer Center)
Cited by 192
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k